CONCOMITANT PSORIASIS VULGARIS AND METABOLIC SYNDROME: A CASE REPORT
Main Article Content
Abstract
Among the various dermatological conditions, psoriasis assumes significant relevance concerning Metabolic Syndrome (MetS). A 57-year-old man presents with pruritic and scaly erythematous plaque on the right ankle persisting for four weeks. The dermatological examination uncovered a noticeable erythematous plaque with a scaly surface on the right ankle, conclusively observed as psoriasis clinical features. Physical examination for metabolic syndrome indicated blood pressure readings of 160/100 mmHg and central obesity with a waist circumference of 98 cm. The psoriasis treatment involves the use of topical corticosteroids and emollients, along with oral metabolic medication consisting of simvastatin and amlodipine, and lifestyle modifications to treat the metabolic disorder. Metabolic syndrome leads to an elevation in the synthesis of pro-inflammatory cytokines, which are shared characteristics with psoriasis. Following comprehensive therapy of ten days of topical treatment and lifestyle modifications, the patient experienced an improvement in the active psoriatic lesions, despite the presence of metabolic disorders.
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
a). Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-NonCommercial-ShareAlike 4.0 International that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b). Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c). Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
References
Ali N, Kuruvila M, Unnikrishnan B (2014) Psoriasis and metabolic syndrome: A case control study. Indian J Derma-tology, Venereol Leprol 80:255-257. doi: 10.4103/0378-6323.132257
Asad F, Rizvi F, Azhar A (2019) Remarka-ble effect of topical betamethasone valerate 0.1% on progress of psoriasis disease. Prof Med J 26:1542-1545. doi: 10.29309/TPMJ/2019.26.09.4020
Debbaneh M, Millsop JW, Bhatia BK, Koo J, Liao W (2014) Diet and psoriasis, part I: Impact of weight loss interven-tions. J Am Acad Dermatol 71:133-140. doi: 10.1016/j.jaad.2014.02.012
Drvar DL, Vlahinić T, Maleš Ž, Turčić P, Čeović R (2019) A modern approach to the treatment of plaque psoriasis. Acta Pharm 69:511-523. doi: 10.2478/acph-2019-0047
Ferdinando LB, Fukumoto PK, Sanches S, Fabricio LHZ, Skare TL (2018) Meta-bolic syndrome and psoriasis: A study in 97 patients. Rev Assoc Med Bras 64:368-373. doi: 10.1590/1806-9282.64.04.368
Fernández‐Armenteros JM, Gómez‐Arbonés X, Buti‐Soler M, Betriu-Bars A, Sanmartin-Novell V, Ortega-Bravo M, Martínez-Alonso M, Garí E, Por-tero-Otín M, Santamaria-Babi L, Cas-anova-Seuma JM (2019) Psoriasis, metabolic syndrome and cardiovas-cular risk factors. A population‐based study. J Eur Acad Dermatology Vene-reol 33:128-135. doi: 10.1111/jdv.15159
Ford ES (2005) Prevalence of the metabol-ic syndrome defined by the interna-tional diabetes federation among adults in the U.S. Diabetes Care 28:2745-2749. doi: 10.2337/diacare.28.11.2745
Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G (2018) Psoriasis and the metabolic syndrome. Clin Dermatol 36:21-28. doi: 10.1016/j.clindermatol.2017.09.005
Gui X, Yu X, Jin H, Zuo Y, Wu C (2018) Prevalence of metabolic syndrome in Chinese psoriasis patients: A hospital‐based cross‐sectional study. J Diabe-tes Investig 9:39-43. doi: 10.1111/jdi.12663
Hao Y, Zhu Y, Zou S, Zhou P, Hu Y, Zhao Q, Gu L, Zhang H, Wang Z, Li J (2021) Metabolic syndrome and pso-riasis: Mechanisms and future direc-tions. Front Immunol 12:711060. doi: 10.3389/fimmu.2021.711060
Jensen P, Skov L (2016) Psoriasis and obesity. Dermatology 232:633-639. doi: 10.1159/000455840
Kim H-N, Han K, Park Y-G, Lee JH (2019) Metabolic syndrome is associated with an increased risk of psoriasis: A nationwide population-based study. Metabolism 99:19-24. doi: 10.1016/j.metabol.2019.07.001
Lee H-J, Kim M (2023) Challenges and fu-ture trends in the treatment of psoria-sis. Int J Mol Sci 24:13313. doi: 10.3390/ijms241713313
Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF (2016) Smoking and risk for psoriasis: a population‐based twin study. Int J Dermatol 55:e72-e78. doi: 10.1111/ijd.13073
Maroto-Morales D, Montero-Vilchez T, Ari-as-Santiago S (2021) Study of skin barrier function in psoriasis: The im-pact of emollients. Life 11:651. doi: 10.3390/life11070651
Mattei PL, Corey KC, Kimball AB (2014) Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): The correlation between dis-ease severity and psychological bur-den in patients treated with biological therapies. J Eur Acad Dermatology Venereol 28:333-337. doi: 10.1111/jdv.12106
Merola JF, Kavanaugh A, Lebwohl MG, Gniadecki R, Wu JJ (2022) Clinical efficacy and safety of psoriasis treatments in patients with concomi-tant metabolic syndrome: A narrative review. Dermatol Ther (Heidelb) 12:2201-2216. doi: 10.1007/s13555-022-00790-2
Pannu S, Rosmarin D (2021) Psoriasis in patients with metabolic syndrome or type 2 diabetes mellitus: Treatment challenges. Am J Clin Dermatol 22:293-300. doi: 10.1007/s40257-021-00590-y
Peralta C, Hamid P, Batool H, Al Achkar Z, Maximus P (2019) Psoriasis and met-abolic syndrome: Comorbidities and environmental and therapeutic impli-cations. Cureus 11:e6369. doi: 10.7759/cureus.6369
Prasad DS, Kabir Z, Revathi Devi K, Peter PS, Das BC (2020) Gender differ-ences in central obesity: Implications for cardiometabolic health in South Asians. Indian Heart J 72:202-204. doi: 10.1016/j.ihj.2020.04.008
Segaert S, Calzavara-Pinton P, de la Cue-va P, Jalili A, Lons Danic D, Pink AE, Thaçi D, Gooderham M (2022) Long-term topical management of psoriasis: The road ahead. J Dermatolog Treat 33:111-120. doi: 10.1080/09546634.2020.1729335
Singh S, Young P, Armstrong AW (2017) An update on psoriasis and metabolic syndrome: A meta-analysis of obser-vational studies. PLoS One 12:e0181039. doi: 10.1371/journal.pone.0181039
Socha M, Pietrzak A, Grywalska E, Pie-trzak D, Matosiuk D, Kiciński P, Ro-linski J (2020) The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials. Arch Med Sci 16:1-7. doi: 10.5114/aoms.2019.90343
Stefanadi EC, Dimitrakakis G, Antoniou C-K, Challoumas D, Punjabi N, Dimi-trakaki IA, Punjabi S, Stefanadis CI (2018) Metabolic syndrome and the skin: a more than superficial associa-tion. Reviewing the association be-tween skin diseases and metabolic syndrome and a clinical decision algo-rithm for high risk patients. Diabetol Metab Syndr 10:9. doi: 10.1186/s13098-018-0311-z
Voiculescu VM, Lupu M, Papagheorghe L, Giurcaneanu C, Micu E (2014) Psori-asis and metabolic syndrome--scientific evidence and therapeutic implications. J Med Life 7:468-471.
Wu JJ, Kavanaugh A, Lebwohl MG, Gni-adecki R, Merola JF (2022) Psoriasis and metabolic syndrome: Implications for the management and treatment of psoriasis. J Eur Acad Dermatology Venereol 36:797-806. doi: 10.1111/jdv.18044
Yuwita W, Gunawan H, Sugiri U, Sandiono D (2017) Metabolic Syndrome in pso-riasis vulgaris patient: A case report. Berkala Ilmu Kesehatan Kulit dan Ke-lamin 28:251-255.